Cadrenal Therapeutics
CVKD2.0906.09% ( +0.120 )
Cadrenal Therapeutics (CVKD)
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditio...
- Open
- 2.010
- High
- 2.090
- Low
- 1.961
- Prev. Close
- 1.970
- Volume
- 17.77K
- Turnover
- 35.80K
- Avg Price
- 2.014
- Bid/Ask Ratio
- --
- Amplitude
- 6.55%
- 52wk High
- 14.640
- Volume Ratio
- 0.13
- Turnover Ratio
- 0.73%
Cadrenal Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 23, 2026Price forecast
$16.67697.45%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 07:06 AM
Cadrenal aligns pipeline into Cardiac Acute Critical Care Franchise, shifts to partnership-driven model
- TradingView · Jul 17 at 03:23 PM
Cadrenal's James J. Ferguson III to Resign as Chief Medical Officer, Separation Effective July 31, 2026
- rttnews · Jul 13 at 08:52 AM
Cadrenal Therapeutics Reports Clinical Data From Phase 2 Study Of CAD-1005
- PUBT · Jul 13 at 08:24 AM
Cadrenal says Phase 2 trial of CAD-1005 cuts thrombotic events by more than 25% in HIT
- PUBT · Jul 10 at 03:06 PM
Cadrenal Therapeutics CMO James Ferguson resigns, effective July 31
- benzinga_article · Jul 6 at 07:05 AM
12 Health Care Stocks Moving In Monday's Pre-Market Session
